Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

606 - My First Patient > Mening > Flashcards

Mening Flashcards

1
Q

Meningococcal disease symptoms

A
  • Meningitis
  • Bacteremia
  • Bacteremic pneumonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Meningitis symptoms

A

pain, headache, neck stiffness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Bacteremia symptoms

A

sepsis and rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Meningococcal Vaccines

A

A, C, Y, W-135
Polysaccharide (MPSV4) - removed from market
and
Conjugate (MCV4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

dosing is different for

A

adolescents and adults with certain med conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

all adolescents

A

2 and 4 dose options for babies

1 dose of MCV4 at age 11-12
1 booster of MCV4 at age 16

only 1 dose if 1st dose after age 16 yrs - not routinely recomm after 19 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

adults with certain med conditions

A

2 doses at least 8 weeks apart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

children at cont’d risk for mening disease who were prev vacc with MCV4

A

additional dose after 3 yrs if 1st was admin at age 2 to 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

persons who have completed the 2-dose primary series and remain at continued risk for meningococcal disease

A

revaccinate every 5 yrs after the last dose of the primary series

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Persons with persistent complement component deficiency or anatomic or functional asplenia

A

1 dose every 5 yrs after completing 2-dose primary series

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HIV patients over the age of 2 mo

A

Men ACYW-135

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

two new mening B vaccs licensed by FDA for ages

A

10-25

2-dose and 3-dose options

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ACIP recommends routine use of MenB vaccines

A

during outbreaks

college campuses that have recently experienced an outbreak of serogroup B meningococcal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Notes about meningococcal b vacc

A
  • must complete series with same vacc
  • can be given at same time with other vaccs, diff sites
  • both men B vaccs recommended for high-risk patients > 10 yrs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Men B not routinely recommended for

A

travelers, HIV patients, revaccination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

CDC recommendations for Men B in an outbreak

A

no upper age limit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Measles

A

Paramyxovirus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Clinical features

A

respiratory transmission

highly contagious 4 days b4 to 4 days after rash onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

incubation

A

10-12 days

20
Q

Early signs

A

(2-4 days) fever 103 or higher,

followed by cough, runny nose, swelling around eye

21
Q

Other sign

A

Rash - first appears in mouth (koplik spots)

22
Q

measles complications

A 
diarrhea
otitis media
pneumonia
encephalitis
death 
hospitalization
23
Q

Mumps

A

Paramyxovirus

24
Q

Clinical feat

A

respiratory transmission

contagious 3 days before to 4 days after onset

25
Q

incubation

A

14-18 days

26
Q

prodrome

A

myalgias, anorexia, headache low-grade fever

27
Q

in first 2 days

A

parotitis

28
Q

20%

A

asymptomatic

29
Q

mumps complications

A 
cns involvement
orchitis
oophoritis
deafness
myocarditis
death
30
Q

Rubella

A

Togavirus (german measles, 3-day measles)

31
Q

clinical features

A

resp transmission (contagious 7 days before rash and 5-7 days after onset

32
Q

incubation

A

14 days (12-23 range)

33
Q

Prodrome

A

rare in children

ow-grade fecer, malaise, URI symptoms

34
Q

Rash

A

musculopapular
starts on face then spreads from head to foot
duration 3 days

35
Q

rubella complications

A

arthralgia or arthritis in adult women

congenital rubella syndrome (cataracts, heart defects, deafness, mental retardation, miscarriage)

36
Q

MMR vaccine

A

(merck) live-attenuated

37
Q

dose

A

2 dose series for children at 12-15mo then 4-6 yrs of age
second dose not a booster, but to revaccinate non-responders

adults born before 1957 immune
born later must have documentation of 1 or more doses of MMR

38
Q

Contraindications

A

allergy to gelatin or neomycin, pregnancy, immunosuppression, receipt of blood products

39
Q

what are the target groups for MMR vaccination

A

all children
all susceptible people at high risk (e.g. health care personnel, college students, travelers, patients with HIV if cd4 count adeq)
adults born n 1957 or later who have never been vacc

40
Q

should a patient with provider-diagnosed measles, mumps, or rubella be considered immune

A

adults born before 1957 considered immune
adults born in 1957 or later
lab evidence or documentation is required, provider diagnosis not adeq.

41
Q

all children

A

2 doses

42
Q

all susceptible patients at high risk for disease

A

2 doses

43
Q

health care personnel born before 1957

A

consider 2 doses

44
Q

adults born in 1957 or later who have not been vacc with MMR

A

at least 1 dose recommended

2nd dose if a risk factor is present

45
Q

recc dose and route of admin for MMR

A

0.5 ml SC

606 - My First Patient (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions